Clinical TrialMay 26, 2026, 08:31 AM
RenovoRx Phase III Sub-Study Supports TAMP for Targeted Drug Delivery
AI Summary
RenovoRx announced the online publication of an abstract from a sub-study of its Phase III TIGeR-PaC clinical trial, ahead of the 2026 ASCO Annual Meeting. The sub-study supports the Trans-Arterial Micro-Perfusion (TAMP) platform for targeted intra-arterial delivery of gemcitabine, demonstrating potential to increase local drug potency and reduce systemic exposure and common side effects. Results showed a direct correlation between increased metabolite levels and reduced CA 19-9, a biomarker for chemotherapy response. The company also noted RenovoCath sales of $1.1 million in 2025 and $563,000 in Q1 2026, and anticipates full enrollment in the TIGeR-PaC trial by June 2026.
Key Highlights
- Phase III TIGeR-PaC sub-study abstract published for 2026 ASCO Annual Meeting.
- Sub-study supports TAMP platform for targeted intra-arterial gemcitabine delivery.
- Demonstrates potential to increase local drug potency and reduce systemic side effects.
- IAG administration correlated with increased metabolite levels and reduced CA 19-9 biomarker.
- Study involved 16 patients across six TIGeR-PaC trial sites.
- RenovoCath sales reached $1.1 million in 2025 and $563,000 in Q1 2026.
- Full enrollment in TIGeR-PaC trial expected June 2026; final data mid-late 2027.
- IAG has Orphan Drug Designation for pancreatic and bile duct cancer.
Price Impact
More from RNXT